Translate this page into:
Case Report
doi:
10.4103/2278-330X.130468
Role of Crizotinib in previously treated non-small-cell lung cancer
1
Department of Medical Oncology, Senior Consultant and Chief of Head and Neck Medical Services, Rajiv Gandhi Cancer Institute and Research Centre, Sector - V, Rohini, New Delhi, India
*Corresponding author: Dr. Sunil Kumar Gupta. drsgonco@rediffmail.com
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Acknowledgment
I am thankful to Pfizer for providing Crizotinib on compassionate grounds for this patient.
References
- A Parikh P, Puri T. Personalized medicine: Lung Cancer leads the way. Indian J Cancer 2013;50:77-9.
- Globocan 2008 data. Available from: http://globocan.iarc.fr/factsheet.asp [Last accessed on 2012 Sep 26].
- Konopa K, Jassem J. The role of pemetrexed combined with targeted agents for non-small cell lung cancer. Curr Drug Targets 2010;11:2-11.
- Reade CA, Ganti AK. EGFR targeted therapy in non-small cell lung cancer: Potential role of cetuximab. Biologics 2009;3:215-24.
- American cancer society. Detailed guide: Lung cancer - non-small cell. Non-small cell lung cancer survival rates by stage. Available from: http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/index [Last accessed on 2012 Mar 22].
- Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
- Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al.: North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
- Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al.: West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
- Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009,361:947-57.
- Gandhi L, Jänne PA. Crizotinib for ALK-rearranged non-small cell lung cancer: A new targeted therapy for a new target. Clin Cancer Res 2012;18:3737-42.
- Shaw AT, Engelmann JA. ALK in lung cancer: Past, present, and future. J Clin Oncol 2013;31:1105-11.
- New 12 National comprehensive cancer network clinical practice guidelines in oncology: Non Small cell lung cancer. Version. 2.2013. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf [Last accessed on 2013 Mar 12].
- Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.